Fumitaka Ohno

Fukuoka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Correction to: Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study.

Correction to: Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study.

Journal: International journal of clinical oncology

Published: June 26, 2025

Phase III Study Investigating the Safety and Efficacy of TM5614 in Combination With Nivolumab for the Treatment of Unresectable Malignant Melanoma: Protocol.

Phase III Study Investigating the Safety and Efficacy of TM5614 in Combination With Nivolumab for the Treatment of Unresectable Malignant Melanoma: Protocol.

Journal: Experimental dermatology

Published: March 03, 2025

Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study.

Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study.

Journal: International journal of clinical oncology

Published: February 21, 2025

KS-NailMel-1: a novel cell line of nail apparatus melanoma.

KS-NailMel-1: a novel cell line of nail apparatus melanoma.

Journal: Human cell

Published: January 16, 2025

Extracellular ATP Contributes to Barrier Function and Inflammation in Atopic Dermatitis: Potential for Topical Treatment of Atopic Dermatitis by Targeting Extracellular ATP.

Extracellular ATP Contributes to Barrier Function and Inflammation in Atopic Dermatitis: Potential for Topical Treatment of Atopic Dermatitis by Targeting Extracellular ATP.

Journal: International journal of molecular sciences

Published: October 29, 2024

A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan.

A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan.

Journal: Frontiers in medicine

Published: September 13, 2023

Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study.

Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study.

Journal: The British journal of dermatology

Published: November 04, 2021

Severe drug eruption induced by cyclin-dependent kinase 4 and 6 inhibitor.

Severe drug eruption induced by cyclin-dependent kinase 4 and 6 inhibitor.

Journal: The Journal of dermatology

Published: February 08, 2021

Inhibition of mite-induced dermatitis, pruritus, and nerve sprouting in mice by the endothelin receptor antagonist bosentan.

Inhibition of mite-induced dermatitis, pruritus, and nerve sprouting in mice by the endothelin receptor antagonist bosentan.

Journal: Allergy

Published: December 17, 2019

Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis.

Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis.

Journal: International journal of molecular sciences

Published: October 31, 2019

Periostin Links Skin Inflammation to Melanoma Progression in Humans and Mice.

Periostin Links Skin Inflammation to Melanoma Progression in Humans and Mice.

Journal: International journal of molecular sciences

Published: December 03, 2018

The pruritogenic mediator endothelin-1 shifts the dendritic cell-T-cell response toward Th17/Th1 polarization.

The pruritogenic mediator endothelin-1 shifts the dendritic cell-T-cell response toward Th17/Th1 polarization.

Journal: Allergy

Published: September 21, 2017

Showing 1-12 of 17

Last Updated: 09/26/2026